The investigators concluded, “ADT-free survival was longer with metastasis-directed therapy than with surveillance alone for oligorecurrent [prostate cancer], suggesting that [metastasis-directed therapy] should be explored further in phase III trials. “

The study was supported by Kom op tegen Kanker.

Piet Ost, MD, PhD, of the Department of Radiotherapy, Ghent University Hospital, is the corresponding author for the Journal of Clinical Oncology article.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.